MECHELEN, BELGIUM and SAFFRON WALDEN, UK--(Marketwire - October 12, 2011) - Galapagos NV
(Euronext: GLPG) announced today that its BioFocus service division has
its collaboration with Chiesi Farmaceutici, a privately owned
pharmaceutical company, for a second time. This extension of the
with Chiesi is valued at EUR2.8 million.
BioFocus and Chiesi began their collaboration in December 2009 and
extended the agreement for a second time, until the end of 2012.
terms of the integrated collaboration agreement, BioFocus will provide
medicinal chemistry resource, biology services, and an option to perform
services, for an undisclosed Chiesi therapeutic program.
"BioFocus' offering complements mid-size pharmaceutical companies like
providing specialized technologies, such as high-throughput
capabilities, and disease-specific expertise," said Dr Chris Newton,
Services for Galapagos. "Our ability to add value to these
organizations has been instrumental in building our substantial number of
"We look forward to entering the third year of our ongoing collaboration
BioFocus. As we continue to progress the project, we plan to further
BioFocus' knowhow in medicinal chemistry and ADME optimization," said Dr
Chiesi, R&D Director and Vice-President of Chiesi Farmaceutici.
About Chiesi Farmaceutici
With over 3,500 employees around the world, the Chiesi Group
distributes successful drugs in 65 countries, and is present on five
with 24 direct affiliates, four research centers, and three production
Respiratory pathologies, special care medicine, and cardiovascular
its traditional areas of expertise where it offers many therapeutic
recognized for their effectiveness. More info at:www.chiesigroup.com
BioFocus provides integrated drug discovery that delivers pre-clinical
candidates in all therapeutic areas with strong capability in
diseases, inflammatory diseases and with a growing track record of
candidates against rare and neglected diseases. BioFocus has
comprehensive drug discovery capabilities that are applied to client
deliver targets, hits, leads and candidate pre-clinical drugs. The
employs over 220 exceptionally qualified and industry experienced
its three research centers in the UK, Switzerland and the Netherlands.
its foundation in 1997, BioFocus has striven to produce high quality
its clients and this quality is assured by ISO9001 qualification
regular, independent inspection of all BioFocus research centers. More
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action. The Company is progressing one of
largest pipelines in biotech, with seven programs in development and over
discovery programs. Through risk/reward-sharing alliances with
Lilly, Janssen Pharmaceutica, Roche and Servier, Galapagos is eligible to
receive up to EUR2.8 billion in downstream milestones, plus royalties. The
Galapagos Group has about 800 employees and operates facilities in six
countries, with global headquarters in Mechelen, Belgium. More info at:
This release may contain forward-looking statements, including,
limitation, statements containing the words "believes,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions,
achievements expressed or implied by such forward-looking statements.
these uncertainties, the reader is advised not to place any undue
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly
obligation to update any such forward-looking statements in this
reflect any change in its expectations with regard thereto or any
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE